Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids

Knobler, Robert; Trautinger, Franz; Radaszkiewicz, T; Kokoschka, E. M.; Micksche, M.

doi:10.1016/0190-9622(91)70036-2

Cited by 105 publications

(42 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Knobler and colleagues conducted a pilot study, in which 7 patients with CTCL were treated with low-dose IFN-a and 13-cis-retinoic acid: 4 of the patients had received prior treatment. 104 Combination therapy resulted in 2 CRs and 2 PRs, which were maintained for up to 15 months. Dreno and colleagues treated 32 patients with MF with IFN-a for 3 months.…”

Section: Topical Bcnumentioning

confidence: 96%

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

Self Cite

391

308

View full text Add to dashboard Cite

Section: Topical Bcnumentioning

confidence: 96%

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

Self Cite

391

308

View full text Add to dashboard Cite

“…Small trials demonstrated major responses with interferon alfa combined with either isotretinoin 6,21 or with etretinate. 7,8,22 Stadler et al 9 documented a major response rate of 59.5% (38.1% complete and 21.4% partial) among 42 patients with stages I or II CTCL with interferon alfa and acitretin, the active metabolite of etretinate.…”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5] The combined use of retinoids and interferons has been studied in CTCL because of their complementary immunomodulating effects and their nonoverlapping toxicity profiles. [6][7][8][9] Retinoids induce IL-12 production, which results in enhanced Th1 activity, whereas the use of interferon alpha/gamma inhibits Th2 cytokine production. 10 Additionally, interferon and retinoids may have synergistic antiangiogenic properties, and both may induce antiproliferative genes.…”

mentioning

confidence: 99%

Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma

Straus

Duvic

Kuzel

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.Bexarotene is one of the most active single agents for the treatment of recurring or refractory cutaneous T‐cell lymphoma (CTCL). Interferon alfa has also been used for many years as an effective treatment for this disease. The results in recent case reports of the combination of bexarotene and interferon alfa have been promising. Based on more extensive results reported with the combination of other retinoids with interferon alfa, the present study attempted to determine the response rate, response duration, and safety of bexarotene (Targretin capsules, Ligand Pharmaceuticals, San Diego, Calif) alone and then with the addition of interferon alfa‐2b (Intron‐A, Schering‐Plough, Kenilworth, NJ).METHODS.Patients with biopsy‐proven CTCL, TNM stages IB, IIA, IIB‐IV, were treated with oral bexarotene 300 mg/m2/day for at least 8 weeks. If a complete response was not seen after 8 weeks, interferon alfa‐2b 3 million units (MU) subcutaneously was added, and increased to 5 MU if tolerated, 3 times a week.RESULTS.A total of 22 patients were enrolled at 5 sites, and 18 patients were assessable for response. Overall response rate for combined bexarotene and interferon alfa was 39% (95% confidence interval [CI]: 17%–64%), including 1 patient with a clinical complete response, 6 patients with partial response, 3 patients with stable disease, and 8 patients with progressive disease. Three partial responses were first noted during the bexarotene‐alone phase. Adverse events were generally manageable, and only 1 patient was withdrawn from study for hypertriglyceridemia.CONCLUSIONS.The addition of interferon alfa‐2b did not increase the response rate that would have been expected with bexarotene alone. Cancer 2007. © 2007 American Cancer Society.

show abstract

“…As suggested above, it is well accepted that treatment with PUVA plus IFN-α administration can produce higher clinical response rates than the use of PUVA alone (68,70). Several small studies have also suggested that a combination of IFN-α with oral retinoids, including bexarotene or 13-cis retinoic acid, may induce rapid responses among patients with extensive skin lesions (65,71). IFN-α induces a variety of salutary immunological effects that may lead to disease clearing.…”

Section: Figurementioning

confidence: 99%

Immunopathogenesis and therapy of cutaneous T cell lymphoma

Kim

Hess²,

Richardson³

et al. 2005

J. Clin. Invest.

325

227

View full text Add to dashboard Cite

Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids

Cited by 105 publications

References 20 publications

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma

Immunopathogenesis and therapy of cutaneous T cell lymphoma

Contact Info

Product

Resources

About